Dr. Martens Reaffirms FY27 Outlook Amid Steady US Wholesale Growth

Dr. Martens has confirmed its full-year guidance for FY27 following a performance in line with initial expectations since the start of the financial year.

Ahead of its Annual General Meeting on Wednesday, the footwear brand confirmed it remains on track to execute the strategic priorities outlined during its full-year results announcement in May, with no adjustments to its outlook.

The company continues to pursue its ambition of becoming the “world’s most-desired premium footwear brand,” focusing on boosting full-price sales in the UK and DACH regions, introducing a new sandal line, implementing innovative retail concepts in key cities, and enhancing operational efficiency through technology advancements.

Dr. Martens highlighted strong performance in its largest market, the US, with wholesale channels delivering particularly encouraging results. Japan and South Korea also continue to show robust demand, while European markets are evolving in line with expectations despite ongoing consumer headwinds.

The update follows the group’s return to profit growth in FY26, driven by continued progress in transitioning to a consumer-first operating model. In May, Dr. Martens indicated that FY27 would mark the commencement of the “scale” phase of its long-term growth strategy, emphasizing increased brand investment and retail store enhancements.

Earlier this year, the business restructured its senior leadership team, introducing dedicated General Managers across key markets to streamline operations and strengthen local consumer engagement.